Not too late to join us today to hear about all of the amazing advances for patients with lung cancer! #lcsm

When Albert Einstein met Charlie Chaplin in 1931, Einstein said, 'What I admire most about your art is its universality. You do not say a word, and yet the world understands you.' 'It's true.' Replied Chaplin, 'But your fame is even greater. The world admires you, when no one…

Thoughtful answers to some very tough audience questions at the #PLCClive24 early stage NSCLC session with Drs. Tina Cascone, Angel Qin, Pamela Samson, MD, Erin Schenk, MD, PhD, Brendon Stiles, Heather Wakelee - MedscapeLIVE #LCSM

Our Presidental Plenary at #AATS2024 kicks off with a lecture from surgeon, inventor, and philanthropist Dr. Patrick Soon Shiong. Hear about his cancer research on April 29 in Toronto: events.aats.org/am24/registrat…

Advance deadline is a week out: Register by 4/17 for lower rates.

Great and timely special issue of the The Annals of Thoracic Surgery , exploring inequities in the care of patients with cardiothoracic disease.
#tssmn #healthequity #thefaceofctsurgery Thoracic Surgery Outcomes Research Network, Inc Leah Backhus MD MPH FACS Ourania Preventza Jackie K. Olive Jo Chikwe

Join us with Isabel Preeshagul and Brendon Stiles next week in Tarrytown/NY for Lung Cancer Research Foundation LCRF Together NY event- rare opportunity to have 3 lung cancer clinician-researchers for lunch- free lunch!

As a less experienced robotic surgeon and one with a team of rotating bedside assistants, I love this....

This....

Shankar Siva Brendon Stiles In my opinion IO+☢️ or🔪could represent the future treatment paradigm in LA-NSCLC, expecially with high PD-L1. The best outcomes derive from IO advent, in sinergy with ☢️or🔪. SPRINT trial is a great example of ChT-free approach. Probably we should define the best sequence IO&☢️

This…

And I love this trial. Despite being non-randomized, it will give us interesting insight into the safety of this strategy and to the multidisciplinary approach that is needed. We are a site and hopefully opening soon!

Brendon Stiles Jeff Bradley, MD Stephen V Liu, MD IASLC Drew Moghanaki 🐕 Shankar Siva Cliff Robinson Narjust Florez, MD, FASCO Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 Jonathan Spicer MD PhD Patrick Forde M.Provencio I think we can start w that results are surprising. We have a ViewPoint JAMA Oncology in-press w Heather McGee, MD PhD that postulates some possibilities why CRT with IO appears detrimental.
We can also start and stop (and other have mentioned) at cross trial comparison is a flawed approach.

Remarkably important finding. We need to decrease the barriers to eligibility for lung cancer screening and make screening criteria amenable to high throughput evaluation in the EMR.